Clinical Trial Search

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…

Primary: Percentage of Patients With Positron Emission Tomography (PET) Negative Disease — 37 Participants

Primary: PART A: Number of Participants Who Complete of 2 Cycles of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) — 30 Participants

Primary: Overall Response After 3 Cycles of Botezomib Plus ICE (BICE) Versus Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed/Refractory Classical Hodgkin…

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Progression-free Survival at 36 Months — 93.1; 89.7 percentage of participants — p=0.9669

Primary: Incidence of Dose-limiting Toxicity (DLT), Phase I Patients Only — 1; 0; 3; 0 Participants

Primary: Event-Free Survival (EFS) — 9 Participants

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Median Progression Free Survival (PFS) — 13.8 years

Primary: Phase 1: Determination of Maximum Tolerated Dose (MTD) First Without and Then With Administration of Prophylactic G-CSF. — 2; 3; 4; 5 mg/m2

Primary: Number of Participants With a Response — 17; 28; 8; 5 participants

Primary: Maximum Tolerated Dose (MTD) of Everolimus With Panobinostat — 10; 20 mg, orally

Primary: Progression Free Survival (PFS) — 6.6 months